Immunic Announces Completion Of Enrollment For Both Phase 3 Ensure Trials In Relapsing MS And Presents Additional Data Underlining Positive Outcome Of Phase 2 Calliper Trial In Progressive MS

Immunic Inc IMUX:

• IMMUNIC ANNOUNCES COMPLETION OF ENROLLMENT FOR BOTH PHASE 3 ENSURE TRIALS IN RELAPSING MS AND PRESENTS ADDITIONAL DATA UNDERLINING POSITIVE OUTCOME OF PHASE 2 CALLIPER TRIAL IN PROGRESSIVE MS

• IMMUNIC INC - TOP-LINE DATA FOR PHASE 3 ENSURE TRIALS EXPECTED END OF 2026